Peter J Greasley

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 10

Top Topics

Top Venues

Journal of clinical pharmacology

Clinical pharmacology and therapeutics

Journal of the American Society of Nephrology : JASN

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics 116 (3) (2024)
J David Smeijer, Victor S Wasehuus, Neeraj Dhaun, Jose Luis Gorriz Teruel, Maria José Soler, Magnus Åstrand, Anne-Kristina Mercier, Peter J Greasley, Philip Ambery, Hiddo J Lambers Heerspink
Effects of Zibotentan Alone and in Combination with Dapagliflozin on Fluid Retention in Patients with CKD. Journal of the American Society of Nephrology : JASN (2024)
Anne-Kristina Mercier, Sebastian Ueckert, Mikael Sunnåker, Bengt Hamrén, Philip Ambery, Peter J Greasley, Magnus Åstrand
From Plan to Pivot: How Model-Informed Drug Development Shaped the Dose Strategy of the Zibotentan/Dapagliflozin ZENITH Trials. Clinical pharmacology and therapeutics (2024)
Subodh Verma, Sunder Mudaliar, Peter J Greasley
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors. Advances in therapy (2023)
Iain B Squire, Anders Gabrielsen, Peter J Greasley, Linda Wernevik, Judith Hartleib-Geschwindner, Julie Holden, Susanne Johansson, Anna Rudvik, José Sánchez, Krister Bamberg, Johanna Melin, Andrew Whittaker
Effect of AZD9977 and spironolactone on serum potassium in heart failure with preserved or mildly reduced ejection fraction, and renal impairment: A randomized trial. Clinical and translational science 15 (10) (2022)
Yasunori Aoki, Claudia S Cabrera, Mario Ouwens, Krister Bamberg, Jenny Nyström, Itamar Raz, Benjamin M Scirica, Bengt Hamrén, Peter J Greasley, Dinko Rekić
Bilirubin levels and kidney function decline: An analysis of clinical trial and real world data. PloS one 17 (6) (2022)
Taha Sen, Rosalie A Scholtes, Peter J Greasley, David Z I Cherney, Claire C J Dekkers, Marc G Vervloet, Alexander H J Danser, Sean J Barbour, Cecilia Karlsson, Ann Hammarstedt, Qiang Li, Gozewijn D Laverman, Petter Bjornstad, Daniel H van Raalte, Hiddo J Lambers Heerspink
Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND. Diabetes, obesity & metabolism 24 (8) (2022)
Hongtao Yu, Sanchita Basu, Weifeng Tang, Robert C Penland, Peter J Greasley, Jan Oscarsson, David W Boulton, Melissa K Hallow
Predicted Cardiac Functional Responses to Renal Actions of SGLT2i in the DAPACARD Trial Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology (2021)
Hongtao Yu, Weifeng Tang, Peter J Greasley, Robert C Penland, David W Boulton, Melissa K Hallow
Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis. Journal of clinical pharmacology 61 (5) (2020)
Andrew J King, Matthew Siegel, Ying He, Baoming Nie, Ji Wang, Samantha Koo-McCoy, Natali A Minassian, Qumber Jafri, Deng Pan, Jill Kohler, Padmapriya Kumaraswamy, Kenji Kozuka, Jason G Lewis, Dean Dragoli, David P Rosenbaum, Debbie O'Neill, Allein Plain, Peter J Greasley, Ann-Cathrine Jönsson-Rylander, Daniel Karlsson, Margareta Behrendt, Maria Strömstedt, Tina Ryden-Bergsten, Thomas Knöpfel, Eva M Pastor Arroyo, Nati Hernando, Joanne Marks, Mark Donowitz, Carsten Alexander Wagner, Robert Todd Alexander, Jeremy S Caldwell
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability. Science translational medicine 10 (456) (2019)